Sellas Life Sciences Group Inc.
06/02/2026 | Press release | Distributed by Public on 06/02/2026 06:31
Material Event (Form 8-K)
| Item 8.01 | Other Events |
As previously reported, as of March 31, 2026, SELLAS Life Sciences Group, Inc. (the "Company") had $107.1 million of cash and cash equivalents.
Subsequent to March 31, 2026, in April and May 2026, the Company received approximately $28.7 million in proceeds from the exercise of common stock warrants.
As of June 2, 2026, the Company had 196,632,574 shares of common stock outstanding.
Sellas Life Sciences Group Inc. published this content on June 02, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on June 02, 2026 at 12:33 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]